1-4 of 4
Philip T Murphy, MD MRCPath
Close
Sort by
Journal Articles

Prognostic Significance of WT1 and PRAME Gene Expression in Bone Marrow Samples of MDS and AML Patients Treated with Azacytidine

Claire N Andrews, MB BAO BCh LRCPI SI MRCPI, Karen Murphy, FRCP, FRCPath, Sinead Moran, Patrick Thornton, Nichola Harten, Philip T Murphy, MD MRCPath
Journal: Blood
Blood (2014) 124 (21): 5599.
https://doi.org/10.1182/blood.V124.21.5599.5599
Published: 2014
Journal Articles

Impact Of Dialysis-Dependent Renal Failure At Time Of Myeloma Diagnosis On Overall Survival - a 15-Year Single Centre Analysis

Philip T Murphy, MD, MRCPath, Cherisse Baldeo, MB, Patrick O'Kelly, Jeremy Sargant, MB, Patrick Thornton, MB, Mary McCloy, MB, MRCP, MRCPath, Peter Conlon, MB, Colm Magee, MB, Mark Denton, MB, John Quinn, MB, PhD
Journal: Blood
Blood (2013) 122 (21): 3230.
https://doi.org/10.1182/blood.V122.21.3230.3230
Published: 2013
Journal Articles

Psychometric Performance Of The EORTC Quality-Of-Life Core Questionnaire (QLQ-C30) and QLQ-Multiple Myeloma (QLQ-MY20) In Relapsed/Refractory Multiple Myeloma (RRMM)

Xavier Leleu, MD, PhD, Maria Teresa Petrucci, MD, Manfred Welslau, Isabelle Vande Broek, Philip T Murphy, MD, MRCPath, Andrew Bottomley, PhD, Pamela Bacon, Philip Lewis, PhD, Hélène Gilet, MSc, Benoit Arnould, PhD, Charalampia Kyriakou
Journal: Blood
Blood (2013) 122 (21): 1721.
https://doi.org/10.1182/blood.V122.21.1721.1721
Published: 2013
Journal Articles

Continued Treatment Duration, Drug dosing  and Health-Related Quality Of Life (HRQoL) Of Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Receiving 2 nd and 3 rd Line Treatments: Results From a European Multicentre Study

Maria Teresa Petrucci, MD, Xavier Leleu, MD, PhD, Charalampia Kyriakou, Isabelle Vande Broek, PhD, Philip T Murphy, MD, MRCPath, Philip Lewis, PhD, Pamela Bacon, Benoit Arnould, PhD, Manfred Welslau
Journal: Blood
Blood (2013) 122 (21): 5368.
https://doi.org/10.1182/blood.V122.21.5368.5368
Published: 2013